1859

1859 is a biotechnology company focused on discovering and developing the next generation of therapies. The company combines artificial intelligence with empirical screening data to discover new small-molecule drugs for emerging disease targets. The platform can identify, synthesize, and test high-potential small molecules on a large scale. By simultaneously exploring billions of molecular starting points and rapidly synthesizing bead-encoded libraries tailored to proprietary pico-scale screening platforms, 1859 can effectively discover, generate insights, and optimize these discoveries within shorter iteration cycles.